Discovery
Medicinal Chemistry Services
Discovery ADME
- Metabolic Stability
- CYP Interaction
- Permeability & Transporters
- Physicochemical Properties
- Protein Binding
›
›
›
›
›
›
›
studies
Ciraparantag is in clinical development as a reversal agent for various anticoagulants including non-vitamin K oral anticoagulants (NOACs). Ciraparantag was previously shown to reverse the anticoagulant effects of edoxaban and enoxaparin, as measured by whole blood clotting time (WBCT).
Register to gain access to gated resources.
Thank you for registering!
You may now view the resource below.
Frontage Laboratories websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies, and their use, please see our privacy policy.
Accept Privacy Policy